Increased @entity413 levels are associated with the generation of advanced glycation endproduct (AGE) modifications. Interaction between AGE-modified @entity2483 and immune cells is believed to have an important role in the development of @entity455 in @entity6 . @entity14625 ( @entity11999 ) is one type of reactive @entity4975 that gives rise to AGE modification. The present study analyzed whether autoantibodies against @entity11999 -modified epitopes of the low-density lipoprotein @entity755 ( @entity755 ) 100 predict cardiovascular events. A library consisting of 302 peptides comprising the complete @entity755 molecule was screened to identify peptides targeted by @entity11999 -specific autoantibodies. Peptide (p) 220 ( @entity755 amino acids 3286-3305) was identified as a major target. Baseline IgM and IgG against @entity11999 -peptide 220 (p220) were measured in 700 individuals from the Malm   Diet and Cancer Cohort. A total of 139 cardiovascular events were registered during the 15-y follow-up period. Controlling for major cardiovascular risk factors demonstrated that subjects in the lowest tertile of @entity11999 -p220 IgM had an increased risk for cardiovascular events (hazard ratio [95% confidence interval]: 2.07 [1.22-3.50]; p(trend) = 0.004). Interestingly, the association between @entity11999 -p220 IgM and cardiovascular events remained and even tended to become stronger when subjects with prevalent @entity6 were excluded from the analysis (2.51 [1.37-4.61]; p(trend) = 0.002). @entity11999 -p220 IgM was inversely associated with blood @entity413 , but not with oxidized low-density lipoprotein. Finally, we demonstrate that anti- @entity11999 -p220 IgM is produced by B1 cells. These data show that subjects with low levels of IgM recognizing @entity11999 -modified p220 in @entity755 have an increased risk to develop cardiovascular events and that this association is present in nondiabetic subjects.

Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified XXXX Peptide Predict Cardiovascular Events in Nondiabetic Subjects.

@entity14625 :: ('MESH:D011765', 'Chemical') :: ['Methylglyoxal'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular complications'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity11999 :: ('CHEBI:31794', 'Chemical') :: ['MGO'] @entity755 :: ('338', 'Gene') :: ['apoB', 'apolipoprotein B', 'apoB100'] @entity2483 :: ('MESH:C566443', 'Disease') :: ['plaque components'] @entity4975 :: ('D000079', 'Chemical') :: ['aldehyde'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity755 :: (338,Gene) :: ['Apolipoprotein B100']
